Evidence map›Paper›PMID 35495549›Full record

ArticleCurrent opinion in toxicology2022

Kidney microphysiological models for nephrotoxicity assessment.

Anish Mahadeo, Catherine K Yeung, Jonathan Himmelfarb, Edward J Kelly

Abstract read
In one paragraph

Article in Current opinion in toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anish MahadeoDepartment of Pharmaceutics, University of Washington, Seattle, WA.
Catherine K YeungDepartment of Pharmacy, University of Washington, Seattle, WA.
Jonathan HimmelfarbThe Kidney Research Institute, University of Washington, Seattle, WA.
Edward J KellyDepartment of Pharmaceutics, University of Washington, Seattle, WA.

Funding

XENOBIOTIC BIOTRANSFORMATION AND DISPOSITIONP30ES007033 · NIEHS · UNIVERSITY OF WASHINGTON · PI Nicole Ann Errett · 1995 to 2026
$42.5M
Pharmacological Sciences SupplementT32GM007750 · NIGMS · UNIVERSITY OF WASHINGTON · PI ATKINS, WILLIAM M · 1985 to 2023
$12.6M
Using iPSCs to model patient outcomes in nephrotic syndromeUH3TR000504 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2014 to 2016
$6.1M
Tissue Chip Data to the Microphysiology Systems Database (MPS-Db) Supplement to A Microphysiological System for Kidney Disease Modeling and Drug Efficacy TestingUH3TR002158 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2019 to 2021
$4.2M
A Microphysiological System for Kidney Disease Modeling and Drug Efficacy TestingUG3TR002158 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2017 to 2018
$2.9M
Safety and Efficacy of Human Clinical Trials Using Kidney-on-a-Chip Microphysiological SystemsUH3TR003288 · NCATS · UNIVERSITY OF WASHINGTON · PI FREEDMAN, BENJAMIN SOLOMON, HIMMELFARB, JONATHAN · 2022 to 2024
$2.3M
A Tissue Engineered Human Kidney Microphysiological SystemUH2TR000504 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2012 to 2013
$2.1M
Safety and Efficacy of Human Clinical Trials Using Kidney-on-a-Chip Microphysiological SystemsUG3TR003288 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN, KRETZLER, MATTHIAS · 2020 to 2021
$1.7M
Modulation of drug transport at the renal proximal tubule by uremic solutes – implications in chronic kidney diseaseR01GM121354 · NIGMS · UNIVERSITY OF WASHINGTON · PI YEUNG, CATHERINE K. · 2017 to 2021
$1.5M
Effects of microgravity on the structure and function of proximal and distal tubule MPSUH3TR002178 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN, KELLY, EDWARD J · 2019 to 2020
$842k
Effects of microgravity on the structure and function of proximal and distal tubule MPSUG3TR002178 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN, KELLY, EDWARD J · 2017 to 2018
$769k
CKDu and Ochratoxin-A: risk assessment studies in a microphysiological systemR21ES031359 · NIEHS · UNIVERSITY OF WASHINGTON · PI KELLY, EDWARD J · 2020 to 2021
$404k
NCATS NIH HHS UG3 TR002158NCATS NIH HHS UG3 TR002178NCATS NIH HHS UG3 TR003288NCATS NIH HHS UH2 TR000504NCATS NIH HHS UH3 TR000504NCATS NIH HHS UH3 TR002158NCATS NIH HHS UH3 TR002178NCATS NIH HHS UH3 TR003288NIEHS NIH HHS P30 ES007033NIEHS NIH HHS R21 ES031359NIGMS NIH HHS R01 GM121354NIGMS NIH HHS T32 GM007750
6 · The paper itself

Abstract

Nephrotoxicity testing is an important step in preclinical development of new molecular entities (NMEs) and has traditionally been performed in 2-D cell culture systems and animal models. However, 2-D culture systems fail to replicate complex

Identifiers

PMID35495549
PMCPMC9053105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.